As of December 15, 2025, Enanta Pharmaceuticals Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $14.73, this represents a potential upside of -563.3%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -574.9% |
| Potential Upside (10-year) | -563.3% |
| Discount Rate (WACC) | 6.4% - 9.9% |
Revenue is projected to grow from $65 million in 09-2025 to $89 million by 09-2035, representing a compound annual growth rate of approximately 3.2%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 09-2025 | 65 | 3% |
| 09-2026 | 69 | 5% |
| 09-2027 | 70 | 2% |
| 09-2028 | 72 | 3% |
| 09-2029 | 77 | 6% |
| 09-2030 | 80 | 4% |
| 09-2031 | 81 | 2% |
| 09-2032 | 84 | 4% |
| 09-2033 | 86 | 2% |
| 09-2034 | 88 | 2% |
| 09-2035 | 89 | 2% |
Net profit margin is expected to improve from -125% in 09-2025 to -125% by 09-2035, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 09-2025 | (82) | -125% |
| 09-2026 | (86) | -125% |
| 09-2027 | (88) | -125% |
| 09-2028 | (91) | -125% |
| 09-2029 | (96) | -125% |
| 09-2030 | (100) | -125% |
| 09-2031 | (102) | -125% |
| 09-2032 | (106) | -125% |
| 09-2033 | (108) | -125% |
| 09-2034 | (110) | -125% |
| 09-2035 | (112) | -125% |
with a 5-year average of $9 million. Projected CapEx is expected to maintain at approximately 12% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 09-2026 | 10 |
| 09-2027 | 11 |
| 09-2028 | 11 |
| 09-2029 | 10 |
| 09-2030 | 9 |
| 09-2031 | 9 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 38 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2026 | (80) | (2) | 8 | 2 | (89) |
| 2027 | (80) | (2) | 9 | 0 | (87) |
| 2028 | (83) | (2) | 9 | 0 | (91) |
| 2029 | (91) | (2) | 9 | 0 | (99) |
| 2030 | (95) | (2) | 10 | 0 | (103) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -574.9% |
| 10-Year DCF (Growth) | 0.00 | -563.3% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Enanta Pharmaceuticals Inc (ENTA) a buy or a sell? Enanta Pharmaceuticals Inc is definitely a sell. Based on our DCF analysis, Enanta Pharmaceuticals Inc (ENTA) appears to be overvalued with upside potential of -563.3%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $14.73.